The FDA has issued a warning about potential serious neurological side effects associated with the arthritis medication Librela for dogs. The drug, which was approved by the FDA last year, has been linked to seizures, loss of muscle control, and even death in some cases. According to a recent review by the FDA, more than 3,600 incidents of negative effects of the drug on dogs’ health have been documented between January 2023 and March 2024.
The manufacturer of Librela, Zoetis, has defended the safety and effectiveness of the medication, stating that over 21 million doses have been distributed globally with rare side effects reported. Dr. Richard Goldstein, Zoetis’ chief medical officer, reassured that they stand behind the drug as safe and effective.
However, pet owners have reported severe illnesses and fatalities in their dogs after receiving the treatment. The FDA is advising caution while investigating these potential risks and urges veterinarians and pet owners to have transparent discussions about treatment decisions.
Overall, while Zoetis maintains the safety and effectiveness of Librela, the FDA’s warning has raised concerns about the possible neurological side effects associated with the medication. Pet owners are advised to monitor their dogs closely for any unusual symptoms and to consult with their veterinarians if any concerns arise. Further research and monitoring of the drug’s effects on dogs are ongoing to ensure the safety and well-being of pets receiving this treatment.
Source
Photo credit www.ndtv.com